By: ABRS- Academic Team
Introduction
Clinical trial oversight is not simply a matter of reviewing activities after they occur. It is an ongoing sponsor responsibility that connects trial design, execution, data quality, participant protection, and decision-making throughout the study lifecycle. The ICH E6(R3) Guideline for Good Clinical Practice emphasizes that sponsors should maintain oversight of trial-related activities and ensure that the processes and information generated during a study are of sufficient quality to support reliable results and appropriate decisions.
Importantly, effective oversight does not mean applying the same level of control to every activity. ICH E6(R3) describes oversight measures as fit for purpose and proportionate to the complexity and risks of the trial, including the oversight of investigators and service providers. This risk-based perspective shifts the focus from simply increasing the volume of review to maintaining visibility over the activities, decisions, and issues that could meaningfully affect participant rights, safety, well-being, or the reliability of trial results. ICH E6(R3)
For clinical operations teams, that makes visibility a practical component of oversight. Clear responsibilities, access to relevant information, defined escalation pathways, and timely follow-up can help sponsors understand where attention is needed as a study progresses. This blog explores three areas that support that visibility across the study lifecycle: clear responsibilities and information flow, risk-proportionate oversight, and effective escalation and follow-through.
Visibility Starts with Clear Responsibilities and Information Flow
Clinical trial oversight begins with a clear understanding of who is responsible for each activity and how relevant information moves between the sponsor, investigators, and service providers. The ICH E6(R3) Guideline for Good Clinical Practice states that agreements with investigators, institutions, service providers, and other parties involved in a trial should be documented before the corresponding activities begin. When trial-related activities are transferred to a service provider, those responsibilities should also be clearly documented, while activities that have not been specifically transferred remain with the sponsor. European Medicines Agency
Clear delegation, however, is only one part of maintaining oversight. Sponsors also need access to information that allows them to understand how transferred activities are being performed. ICH E6(R3) specifically notes that sponsors should have access to relevant information, such as procedures and performance metrics, when selecting and overseeing service providers. This creates an important distinction between delegating execution and losing visibility: a sponsor may rely on external functional expertise while still maintaining access to the information needed for appropriate oversight. European Medicines Agency
This becomes particularly relevant when several organizations or functional teams contribute to the same study. Information may move across clinical operations, data management, safety, regulatory functions, laboratories, technology providers, and other partners. From an operational perspective, clearly defined reporting pathways and decision responsibilities can help ensure that relevant information reaches the appropriate stakeholders rather than remaining isolated within individual functions. The FDA’s E6(R3) Good Clinical Practice guidance similarly emphasizes documented agreements and appropriate sponsor oversight of investigators and service providers, reinforcing the importance of transparency across transferred activities. U.S. Food and Drug Administration
Visibility therefore depends less on the sponsor being involved in every operational detail and more on having a structure that makes responsibilities, performance information, and emerging issues accessible when needed. Establishing that structure early can provide a clearer foundation for the risk-based oversight and escalation processes that continue throughout the study lifecycle.
Oversight Should Follow Risk, Not Volume of Activity
Effective oversight is not defined by how many activities are reviewed or how frequently teams collect information. A risk-proportionate approach directs attention toward the aspects of a trial that could meaningfully affect participant rights, safety and well-being, or the reliability of trial results. The ICH E6(R3) Guideline for Good Clinical Practice describes risk management as an ongoing process in which sponsors identify and evaluate risks before trial initiation and throughout trial conduct, considering trial processes, systems, data handling, and service provider activities. European Medicines Agency
This approach also means that oversight should be adapted to the significance of the risk rather than applied uniformly across every trial activity. ICH E6(R3) states that risk controls should be proportionate to the importance of a risk to participants and to the reliability of trial results. The European Medicines Agency’s overview of ICH E6(R3) similarly describes the guideline as promoting risk-based, proportionate, and fit-for-purpose approaches to trial conduct. In practice, this provides a framework for focusing oversight where additional attention is justified rather than creating unnecessary operational burden across all areas of a study. European Medicines Agency
Risk priorities may also change as a study progresses. New information can emerge through monitoring activities, operational performance, safety data, protocol deviations, data review, or the performance of external providers. The UK MHRA guidance on quality and risk proportionality reinforces the use of quality-by-design, risk-based quality management, and proportionate oversight in clinical trials. From an operational perspective, this supports treating risk assessment as a continuing activity rather than a document completed at study start and left unchanged. GOV.UK
For clinical operations teams, maintaining visibility therefore involves knowing which risks require attention, what information can indicate that those risks are changing, and when the level of oversight should be adjusted. A proportionate approach does not reduce accountability; it helps align oversight activities with the areas most relevant to participant protection and reliable trial results throughout the study lifecycle.
Escalation and Follow-Through Make Oversight Actionable
Visibility only becomes useful when emerging issues can reach the right decision-makers and lead to an appropriate response. The FDA E6(R3) Good Clinical Practice guidance states that sponsors should ensure appropriate and timely escalation and follow-up of issues so that necessary actions can be implemented without unnecessary delay. This expectation connects oversight with action: identifying a concern is only the beginning; teams also need a clear pathway for determining who should review it, what response is appropriate, and how the issue will be followed through to resolution. U.S. Food and Drug Administration
Effective escalation also depends on context. Not every operational issue requires the same level of attention, and escalation pathways should reflect the potential impact on participant protection, trial conduct, and the reliability of results. E6(R3) places escalation within a broader oversight framework that is intended to be fit for purpose and tailored to trial complexity and risk. From an operational perspective, this supports defining thresholds and responsibilities in advance so that teams can distinguish routine issues from those requiring additional sponsor attention. U.S. Food and Drug Administration
Monitoring information can provide an important signal within that process. The FDA guidance on risk-based monitoring of clinical investigations describes monitoring as a quality control tool and provides recommendations for addressing and communicating monitoring results. When findings, trends, or deviations are communicated through established channels, they can contribute to a broader understanding of whether existing controls remain appropriate or whether additional action may be needed. U.S. Food and Drug Administration
Follow-through is therefore as important as escalation itself. Clinical operations teams need visibility not only into what was identified, but also into how the issue was assessed, what actions were assigned, and whether those actions addressed the underlying concern. Maintaining that continuity helps connect day-to-day operational information with sponsor oversight and supports a more responsive approach as conditions evolve throughout the study lifecycle.
Conclusion:
Maintaining clinical trial oversight across the study lifecycle depends on more than periodic review. It requires a structure that keeps responsibilities visible, aligns attention with meaningful risks, and ensures that emerging issues can be escalated and followed through appropriately.
The principles reflected in ICH E6(R3), together with current FDA and MHRA guidance, point toward an oversight model that is proportionate, informed by relevant data, and responsive to changing trial conditions. For sponsors, this means creating operational pathways that allow information to move effectively across functions, service providers, and decision-makers throughout the study.
As clinical trials involve more specialized partners, technologies, and distributed activities, maintaining visibility can help sponsors preserve continuity between strategy and execution. Clear governance, defined escalation pathways, and risk-based oversight can support more informed decision-making without requiring the sponsor to intervene in every operational detail.
For organizations using integrated support models, including FSP or broader clinical operations structures, these same principles can help connect functional expertise with sponsor processes and oversight needs. Any description of how ABRS specifically applies these principles through Clinical Oversight Management or FullSpectrum should be validated internally before publication.
